FDA Approved: VYZULTA — Supplemental Application (Bausch & Lomb Incorporated)

View source ↗

Summary

The FDA approved a supplemental application for VYZULTA (latanoprostene bunod) submitted by Bausch & Lomb Incorporated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Hypertension
• Open-angle Glaucoma

Drugs mentioned

• VYZULTA (latanoprostene bunod)

Snippet

SUPPL AP for VYZULTA (LATANOPROSTENE BUNOD)